Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age

NCT04450004 is registered in ClinicalTrials.gov with Medicago as lead sponsor.

NCT NCT04450004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04450004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age
Lead sponsor
Medicago
Phase
Phase 1
Overall status
Completed
Start date
July 10, 2020
Completion date
August 30, 2021
Enrollment
180 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov 2